| AFP联合AFP-L3、ALP和AFU检测在原发性肝癌诊断中的价值 |
| Alternative Title | Diagnostic Value of Combined Detection of AFP, AFP-L3, ALP and AFU Levels in Primary Liver Cancer
|
| 高翔 |
| Thesis Advisor | 卢启明
|
| 2012-05-18
|
| Degree Grantor | 兰州大学
|
| Place of Conferral | 兰州
|
| Degree Name | 硕士
|
| Keyword | 原发性肝癌
甲胎蛋白
甲胎蛋白异质体
甲胎蛋白异质体
-L-岩藻糖苷酶
|
| Abstract | 目的: 探讨甲胎蛋白联合AFP-L3、ALP和AFU检测在原发性肝癌的诊断价值。
方法: 使用化学发光法分别检测原发性肝癌患者(142例)、肝硬化患者(106例)和正常对照组(125例)中AFP、AFP-L3、ALP和AFU的血清含量，分析这些肿瘤标记物测定值对原发性肝癌诊断的阳性率。
结果: 原发性肝癌组AFP、AFP-L3、ALP、AFU的阳性率分别为74.6%、73.9%、42.2%、76.3%，与肝硬化组相比较，差异有统计学意义(P<0.01)。四项检测指标联合对原发性肝癌诊断的阳性率为98.6%，与单项检测指标相比差异有统计学意义(P<0.01)。
结论:AFP、AFP-L3、ALP和AFU对原发性肝癌的诊断有一定的临床应用价值，联合检测可提其诊断准确率。
关键词:原发性肝癌；甲胎蛋白；甲胎蛋白异质体；甲胎蛋白异质体；-L-岩藻糖苷酶 |
| Other Abstract | Objective: To investigate the diagnostic value of combined detection of AFP, AFP-L3, ALP and AFU levels in primary liver cancer.
Methods: The serum levels of AFP, AFP-L3, ALP and AFU were measured in 142 cases with primary liver cancer, 106 cases with liver cirrhosis group and 125 healthy subjects by chemiluminescence method. The positive rate of diagnosing primary liver cancer was analyzed.
Results: Positive rate of AFP, AFP-L3, ALP and AFU for primary hepatic cancer was 74.6%, 73.9%, 42.2%, 76.3%. Compared with liver cirrhosis group and healthy subjects, the difference was statistically significant (P<0.01). The positive rate of those four serum markers were 98.6%, compared with single examination marker, the difference was statistically significant (P<0.01).
Conclusion: AFP, AFP-L3, ALP and AFU have certain diagnostic value for primary liver cancer. United determination can raise the diagnosis rate of primary liver cancer.
Keywords: Primary liver cancer, AFP, AFP-L3, ALP, AFU |
| URL | 查看原文
|
| Language | 中文
|
| Document Type | 学位论文
|
| Identifier | https://ir.lzu.edu.cn/handle/262010/224244
|
| Collection | 学院待认领
|
| Affiliation | 临床医学院
|
Recommended Citation
GB/T 7714 |
高翔. AFP联合AFP-L3、ALP和AFU检测在原发性肝癌诊断中的价值[D]. 兰州. 兰州大学,2012.
|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
